课题基金 / 基金详情

项目摘要

项目成果

RICHARD David GRANSTEIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is substantial evidence that stress, emotional status and neural activity modulate immunological responsiveness. However, except for endocrine effects, the mechanism(s) of this regulation remain obscure at the cellular and molecular levels. One system that is amenable to establishing mechanistic links is the cutaneous immune system. In the skin, Langerhans cells (LCs), antigen presenting cells in the epidermis, are innervated. Furthermore, our laboratory has previously established that norepinephrine (NE), epinephrine (EPI) and three neuropeptides [calcitonin gene-related peptide (CGRP), pituitary adenylate activating polypeptide (PACAP), and vasoactive intestinal peptide (VIP)] are all able to modulate cutaneous immune responses in vivo and in vitro. This neuro-immunological interaction is probably important in (a) some pathological conditions (atopic dermatitis, psoriasis, autoimmune disorders), (b) the normal responses to invading pathogens and (c) the response to antigens during vaccination. Nevertheless, there are substantial gaps in understanding these pathways. It is not known which intracellular signaling pathway(s) are responsible for mediating the effects of neurotransmitters or if different neurotransmitters influence different pathways. Although nerves influence Th1 responses, it is not clear if they influence Th2 responses or the balance of Th1 to Th2 responses. We propose herein to test the hypothesis that neurotransmitters modulate both Th1- and Th2-dependent immune responses by modulating intracellular signaling pathways, especially the cAMP-dependent inhibition of NFkappaB activation. A correlate of this hypothesis is that the nervous system may have a role in selecting the type of immune response that occurs. This will be done in 3 specific aims: Aim 1 - To identify and study the intracellular signaling events that mediate the effects of NE/EPI, PACAP, VIP, and CGRP on the maturation of LCs. Aim 2 - To determine if neuro-peptides or neurotransmitters modulate the Th2 response, the Th1/Th2 cytokine balance and/or antibody production. Aim 3 - To determine if denervation influences the number of LCs, their maturation state or their capacity to induce contact hypersen-sitivity. By further exploring the types of cutaneous immune responses that are regulated by the nervous system and by determining the molecular mechanisms of this regulation, we will create the knowledge needed for rational design of drugs to modify cutaneous immune responses in pathological and normal. Immune responses in the skin.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cyto.2013.08.005
发表时间: 2013-11
期刊: CYTOKINE
影响因子: 3.8
作者: [Stohl, Lori L., Zang, Julie B., Ding, Wanhong, Manni, Michela, Zhou, Xi K., Granstein, Richard D.]
通讯作者: Granstein, Richard D.
β2-Adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune response.
β2-肾上腺素能激动剂偏置TLR-2和NOD2激活树突状细胞诱导IL-17免疫反应。
DOI: 10.1016/j.cyto.2011.05.013
发表时间: 2011-09
期刊: CYTOKINE
影响因子: 3.8
作者: [Manni, Michela, Granstein, Richard D., Maestroni, Georges]
通讯作者: Maestroni, Georges
DOI: 10.1016/j.bbi.2011.02.007
发表时间: 2011-05
期刊: BRAIN BEHAVIOR AND IMMUNITY
影响因子: 15.1
作者: [Huang, Jing, Stohl, Lori L., Zhou, Xi, Ding, Wanhong, Granstein, Richard D.]
通讯作者: Granstein, Richard D.
DOI: 10.4049/jimmunol.181.9.6020
发表时间: 2008-11-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Ding W, Stohl LL, Wagner JA, Granstein RD]
通讯作者: Granstein RD
12
    Neurotransmitter Regulation of Immunity Through Effects on Endothelial Cells
    • 批准号:
      8702657
    • 项目类别:
    • 资助金额:
      $22.37万
    • 财政年份:
      2014
    • 负责人:
      RICHARD David GRANSTEIN
    • 依托单位:
    Neurotransmitter Regulation of Immunity Through Effects on Endothelial Cells
    • 批准号:
      8826027
    • 项目类别:
    • 资助金额:
      $18.65万
    • 财政年份:
      2014
    • 负责人:
      RICHARD David GRANSTEIN
    • 依托单位:
    Vaccine Development: Purinergic Agonists as Adjuvants
    • 批准号:
      6754602
    • 项目类别:
    • 资助金额:
      $33.6万
    • 财政年份:
      2004
    • 负责人:
      RICHARD David GRANSTEIN
    • 依托单位:
    Vaccine Development: Purinergic Agonists as Adjuvants
    • 批准号:
      6891607
    • 项目类别:
    • 资助金额:
      $33.6万
    • 财政年份:
      2004
    • 负责人:
      RICHARD David GRANSTEIN
    • 依托单位:
    海外基金